Quintrio
Home

PHARMACEUTICAL PREPARATIONS

NeOnc Technologies Holdings, Inc. Common Stock

NTHI

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Last trade $4.39
Day change -$0.15 (-3.30%)
Day range $4.36 – $5.16
Volume 201,401
Market cap $131M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$130.98M
Price / earnings
—
Price / book
-9.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.07×

Profitability

Earnings per share
-$1.59
Return on assets
-492.87%
Return on equity
348.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
0.38×
Quick ratio
0.38×
Cash ratio
0.28×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NTHI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$0$0$0$0$0$0$39.99K
Cost of revenue$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$39.99K
Selling, general and administrative$1.8M$7.83M$4.41M$24.19M$6.22M$5.03M$19.2M
Research and development$1.31M$2.65M$1.29M$1.25M$715.04K$677.33K$998.22K
Total operating expenses$5.83M$14.07M$7.06M$13.7M$6.93M$5.71M$31.94M
Operating income-$5.83M-$14.07M-$7.06M-$13.7M-$6.93M-$5.71M-$31.9M
Interest expense-$97.51K-$402.32K-$982.62K-$478.77K-$869.82K-$241K-$308.92K
Income before taxes-$4.44M-$14.24M-$8.82M-$15.52M-$8.62M-$5.68M-$32.33M
Income taxes$0$0$0$0$0$0$0
Net income-$4.44M-$14.24M-$8.82M-$15.52M-$8.62M-$5.68M-$32.33M
Net income attributable to common shareholders-$7.27M-$14.24M-$8.82M-$15.52M-$8.62M-$5.68M-$32.33M
EBITDA-$5.83M-$14.06M-$7.04M-$13.7M-$6.93M-$5.71M-$31.9M
Basic earnings per share-$0.28-$0.58-$0.38-$0.73-$0.45-$0.30-$1.78
Diluted earnings per share-$0.28-$0.58-$0.38-$0.73-$0.45-$0.30-$1.78

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO

Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.

GlobeNewswire Inc.

NeOnc Is Putting Two Brain Cancer Programs on the Global Stage

NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company, will present data from two investigational brain cancer programs—intranasal NEO100 and oral NEO212—at the Society for Neuro-Oncology annual meeting on November 13, 2026. The company is advancing ambitious plans for a 500-patient international clinical trial across 30 hospitals in three countries, leveraging innovative drug delivery approaches and AI-assisted tumor modeling technology.

GlobeNewswire Inc.

2027 Could Finally Be the Year Cancer Is on the Ropes!

Global cancer research is advancing through AI-supported precision medicine, biomarker-guided treatments, and innovative approaches. Anthropic is supporting pediatric cancer care through the PCX program, while companies like AstraZeneca report survival improvements in gastric cancer with sonesitatug vedotin. Researchers in Japan and South Korea are exploring novel approaches including using cancer cells' own chemistry to produce treatments and reprogramming cancer cells toward normal states.

GlobeNewswire Inc.

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

NeOnc Technologies announced early clinical improvements in a critically ill three-year-old boy treated with investigational intranasal NEO100 through its Compassionate Care program in Abu Dhabi. The patient is now breathing independently without ventilator support and showing renewed leg movement. The company emphasized these observations involve a single patient and do not establish efficacy or predict outcomes in other patients.

GlobeNewswire Inc.

NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors

NeOnc Technologies announced the appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors effective October 9, 2026. The appointment strengthens financial governance as NeOnc advances its clinical programs and expands operations in Abu Dhabi. The Department of Health – Abu Dhabi has granted IND authorization for NEO212, supporting Phase 2 development in the UAE.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.